Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

The first international conference on vascular targeting: meeting overview.

Thorpe PE, Chaplin DJ, Blakey DC.

Cancer Res. 2003 Mar 1;63(5):1144-7.

2.

Vascular targeting agents as cancer therapeutics.

Thorpe PE.

Clin Cancer Res. 2004 Jan 15;10(2):415-27. Review.

3.

AVE8062: a new combretastatin derivative vascular disrupting agent.

Delmonte A, Sessa C.

Expert Opin Investig Drugs. 2009 Oct;18(10):1541-8. doi: 10.1517/13543780903213697. Review.

PMID:
19758109
4.

Current development status of small-molecule vascular disrupting agents.

Chaplin DJ, Horsman MR, Siemann DW.

Curr Opin Investig Drugs. 2006 Jun;7(6):522-8. Review.

PMID:
16784022
5.

Vascular-targeting therapies for treatment of malignant disease.

Siemann DW, Chaplin DJ, Horsman MR.

Cancer. 2004 Jun 15;100(12):2491-9. Review.

6.

Combretastatin A4 phosphate: background and current clinical status.

Young SL, Chaplin DJ.

Expert Opin Investig Drugs. 2004 Sep;13(9):1171-82. Review.

PMID:
15330748
7.
8.

Small molecule vascular disrupting agents: potential new drugs for cancer treatment.

Cai SX.

Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):79-101. Review.

PMID:
18221055
9.

Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises.

Van Langendonckt A, Donnez J, Defrère S, Dunselman GA, Groothuis PG.

Mol Hum Reprod. 2008 May;14(5):259-68. doi: 10.1093/molehr/gan019. Epub 2008 Apr 22. Review.

PMID:
18430758
10.

Combretastatin A4 phosphate.

West CM, Price P.

Anticancer Drugs. 2004 Mar;15(3):179-87. Review.

PMID:
15014350
11.

Molecular imaging of antiangiogenic agents.

Rehman S, Jayson GC.

Oncologist. 2005 Feb;10(2):92-103. Review.

12.

Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.

Cooney MM, Ortiz J, Bukowski RM, Remick SC.

Curr Oncol Rep. 2005 Mar;7(2):90-5. Review.

PMID:
15717941
13.

Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.

McKeage MJ, Baguley BC.

Cancer. 2010 Apr 15;116(8):1859-71. doi: 10.1002/cncr.24975. Review.

14.
15.

Potential of DMXAA combination therapy for solid tumors.

Baguley BC, Wilson WR.

Expert Rev Anticancer Ther. 2002 Oct;2(5):593-603. Review.

PMID:
12382527
16.

Strategy for the development of novel anticancer drugs.

Saijo N, Tamura T, Nishio K.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S97-101. Epub 2003 Jun 18. Review.

PMID:
12856152
17.

Small-molecule cytokine inducers causing tumor necrosis.

Baguley BC.

Curr Opin Investig Drugs. 2001 Jul;2(7):967-75. Review.

PMID:
11757800
18.
19.

Angiogenesis and vascular targeting: relevance for hyperthermia.

Horsman MR.

Int J Hyperthermia. 2008 Feb;24(1):57-65. doi: 10.1080/02656730701829710. Review.

PMID:
18214769
20.

Chemotherapy targeted to tumor vasculature.

Arap W, Pasqualini R, Ruoslahti E.

Curr Opin Oncol. 1998 Nov;10(6):560-5. Review.

PMID:
9818236

Supplemental Content

Support Center